Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Our aim was to investigate the efficacy and safety of initial neoadjuvant endocrine therapy with exemestane alone followed by tailored treatment, either continued exemestane monotherapy or exemestane plus docetaxel–cyclophosphamide (TC) combination therapy, in postmenopausal patients with primary in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Sato, Nobuaki, Masuda, Norikazu, Morimoto, Takashi, Ueno, Takayuki, Kanbayashi, Chizuko, Kaneko, Koji, Yasojima, Hiroyuki, Saji, Shigehira, Sasano, Hironobu, Morita, Satoshi, Ohno, Shinji, Toi, Masakazu
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6745863/
https://ncbi.nlm.nih.gov/pubmed/31361400
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2423
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados